Unlocking the Secret: Interchangeability of Eliquis and apixaban in Anticoagulant Therapy




Anticoagulants like Eliquis which is generic apixaban are prescription medications commonly used to prevent and treat blood clotting disorders. Both medications, which contain the same active ingredient, apixaban, offer effective and interchangeable options for anticoagulant therapy.  

This active ingredient works by inhibiting specific clotting factors in the blood, thereby reducing the risk of clot formation. Eliquis (apixaban) is considered an effective option for anticoagulant therapy and can be used interchangeably with generic apixaban in all cases.  

This article explores the reasons behind their interchangeability and the benefits they provide to patients. 

Makers of Eliquis (generic name: apixaban) 

Eliquis is manufactured by Bristol-Myers Squibb and Pfizer. It is a prescription medication used to reduce the risk of stroke and blood clots in individuals with conditions such as atrial fibrillation.  

The collaboration between Bristol-Myers Squibb and Pfizer has been a factor in the development and distribution of Eliquis as a widely used anticoagulant medication. 

Benefits of apixaban, the active ingredient in Eliquis 

Apixaban offers several benefits, including effective anticoagulation, predictable dosing, favorable safety profiles, and convenience. Which will be further discussed through the article. 

  • Safety Profile   

Eliquis (apixaban) offers a preferable safety profile compared to older anticoagulants. Traditional anticoagulants such as warfarin require frequent monitoring and dose adjustments because of how narrow their therapeutic index is. In contrast, apixaban has a predictable dose-response relationship, thus eliminating the need for routine monitoring, reducing the risk of adverse events, and simplifying the treatment process for healthcare professionals and patients alike.  

Apixaban has a more favorable safety profile compared to older anticoagulants like warfarin. With a predictable dose-response relationship, they eliminate the need for routine monitoring and dose adjustments, simplifying treatment for healthcare professionals and patients.  

Additionally, both medications have shown a lower risk of major bleeding, enhanced patient compliance and providing peace of mind for healthcare providers.  

  • Convenience and Adherence  

Dose adjustments simplifies medication management, improves adherence, and reduces the risk of errors related to dose adjustments. This predictability makes it easier for patients to manage their medication regimen and adhere to their prescribed treatment plan. By removing the complexities associated with monitoring and dose adjustments, Eliquis and apixaban offer a convenient fixed dosing schedule, unlike warfarin which requires frequent dose adjustments based on INR (international normalized ratio) measurements.  

  • Anti-Coagulation effectiveness 

Apixaban works by specifically blocking factor Xa, which is involved in blood clot formation. By inhibiting factor Xa, apixaban reduces the production of thrombin, a key enzyme in clot formation.  

Unlike other clotting proteins, apixaban targets factor Xa with a high level of selectivity and does not depend on antithrombin III for its action. It does not affect other clotting factors like activated protein C, factors IXa and VIIa, or thrombin directly. Additionally, they indirectly inhibit platelet aggregation, which could make it beneficial in preventing both venous and arterial blood clots. 

  • Predictable dosing

Eliquis (apixaban) is an anticoagulant medication that offers predictable dosing regimens. Unlike warfarin, which requires frequent monitoring and dose adjustments based on blood tests, apixaban and Eliquis have fixed dosing schedules. This means that patients can take the same dose each day without the need for regular monitoring or dose changes.  

Patients can follow their prescribed dosing schedule without the need for constant adjustments, making it easier to incorporate the medication into their daily routine. 

Active Ingredient  

Eliquis contains the active ingredient apixaban, which is a direct oral anticoagulant that prevents blood clot formation by inhibiting Factor Xa. Through targeting factor Xa, these medications prevent the formation of harmful blood clots, the risk of thromboembolic events.  


One of the strongest factors supporting the interchangeability of Eliquis and generic apixaban is their bioequivalence.  

Bioequivalence is the similarity in the rate and extent of absorption of the active ingredient into the bloodstream, they have comparable pharmacokinetic properties having consistent and predictable anticoagulation effects. 

Canadian generic versions  



MAR-apixaban, APO-apixaban, and TARO-apixaban are generic versions of Eliquis (apixaban) available in Canada. These generic brands offer the same active ingredient as the brand name Eliquis, providing equivalent therapeutic benefits at a more affordable cost. By providing a cost-effective alternative.  

These generic versions increase accessibility to essential anticoagulant therapy for patients while maintaining the same level of effectiveness and safety as the brand name medication. 

 Healthcare professionals can consider these generic options as interchangeable alternatives when prescribing anticoagulant therapy for their patients. 

Therapeutic Efficacy  

Eliquis (apixaban) has shown superior efficacy in clinical trials, outperforming traditional anticoagulants like warfarin in preventing stroke and systemic embolism in atrial fibrillation patients. They are also effective in treating and preventing venous thromboembolism (VTE) after orthopedic surgery. 

Interchangeability and Cost Savings  

The interchangeability of Eliquis and generic apixaban allows healthcare providers and patients to optimize treatment outcomes and save money. Generic versions of Eliquis from Canadian online pharmacies offer a cost-effective alternative without compromising efficacy or safety. 

Patients in the US can save even more by ordering from a Canadian pharmacy. This accessibility enhances patient access to effective anticoagulant therapy. 


The interchangeability of Eliquis and apixaban provides flexibility for healthcare professionals and patients in selecting effective anticoagulation therapy. With identical active ingredients, bioequivalence, therapeutic efficacy, safety profile, convenience, and cost-effectiveness, they are valuable options for thromboembolic disorder prevention and treatment.  

For inquiries about prescription medications, contact our team at Jason’s CanadaDrugstore.comby calling 1-800-226 3784 (CAN-DRUG) for assistance from our patient representatives or a licensed Canadian pharmacist.

This article provides medical information to help understand a condition or treatment plan but is not a diagnosis or treatment recommendation. Contact your doctor if you have concerns or symptoms. In case of emergency, call 911.

Be the first to comment

Leave a Reply

Your email address will not be published.